Answers are grounded in this paper and cite their sources.
Risk-based framework enables birabresib use for NUT carcinoma, suggesting broader applications for rare diseases.
This risk-proportionate, CMC-oriented hospital framework enabled the first authorised therapeutic use of birabresib in NUT carcinoma and may be extended to other discontinued small molecules used in regulated access programmes for ultra-rare diseases.
No takes yet. Share an insight, caveat, or question.
Annereau et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: